Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Tonight’s Hot Topic Tuesday revisits injectable weight-loss drugs and the new discoveries coming out about the medications.

The lawsuit said the union’s health plan allowed coverage of Xenical to treat obesity but not newer products such as Wegovy ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Mini meals with bite size portions are meant to appeal to people taking GLP-1 weight-loss drugs that reduce appetite.

Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

In the second part of his Pharma Commerce video interview, Hyung Heon Kim, CEO of MetaVia, explains how dual-action metabolic therapies can address clinical or tolerability gaps observed in ...

University of Florida researchers said a new study could lead to a universal cancer shot, while digital health earnings ...

According to Research by SNS Insider, The U.S. GLP-1 Receptor Agonist Market to Reach USD 113.13 Billion by 2032, Driven by Rising Prevalence of Type 2 Diabetes and Demand for Obesity-Related ...

At the heart of equitable healthcare lies a critical truth: representation matters.  BlackDoctor.org spoke with Dr. Adrelia ...